Tumor Biology

, Volume 37, Issue 2, pp 2621–2627 | Cite as

HEPACAM inhibited the growth and migration of cancer cells in the progression of non-small cell lung cancer

  • Huanzhang Shao
  • Yinjie Gu
  • Junli Ding
  • Peihua Lu
  • Tingyan Ruan
  • Wenbin Lu
Original Article


Hepatocyte cell adhesion molecule (HEPACAM), a member of immunoglobulin superfamily, is an adhesion molecule. Although dysregulation of several adhesion molecules has been implicated in the progression of non-small cell lung cancer (NSCLC), the expression profile and functions of HEPACAM in NSCLC remains unknown. In this study, it was found that the expression of HEPACAM was downregulated in NSCLC tissues. Forced expression of HEPACAM in NSCLC cells inhibited the growth and migration of the cancer cells, while knocking down the expression of HEPACAM promoted cell growth, migration, and metastasis. In the molecular mechanism study, HEPACAM was found to be a negative regulator of beta-catenin/TCF signaling. Taken together, this study revealed the suppressive roles of HEPACAM in NSCLC and restoring the function of HEPACAM in NSCLC might be a promising strategy for the therapy.


HEPACAM Non-small cell lung cancer Cell growth and migration Beta-catenin/TCF 


Conflicts of interest



  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Lu S, Azada MC, Ou SH. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lung Cancer. 2015;87:207–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhong K, Chen W, Xiao N, Zhao J. The clinicopathological significance and potential drug target of E-cadherin in NSCLC. Tumour Biol. 2015;36:6139–48.CrossRefPubMedGoogle Scholar
  4. 4.
    Botling J, Edlund K, Lohr M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013;19:194–204.CrossRefPubMedGoogle Scholar
  5. 5.
    Fiori V, Magnani M, Cianfriglia M. The expression and modulation of CEACAM1 and tumor cell transformation. Ann Ist Super Sanita. 2012;48:161–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Barrallo-Gimeno A, Estevez R. GlialCAM, a glial cell adhesion molecule implicated in neurological disease. Adv Neurobiol. 2008;8:47–59.CrossRefGoogle Scholar
  7. 7.
    Arnedo T, Lopez-Hernandez T, Jeworutzki E, et al. Functional analyses of mutations in HEPACAM causing megalencephalic leukoencephalopathy. Hum Mutat. 2014;35:1175–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Tao J, Liu Q, Wu X, et al. Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma. Int J Med Sci. 2013;10:1860–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Moh MC, Zhang T, Lee LH, Shen S. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis. 2008;29:2298–305.CrossRefPubMedGoogle Scholar
  10. 10.
    Moh MC, Lee LH, Yang X, Shen S. HEPN1, a novel gene that is frequently down-regulated in hepatocellular carcinoma, suppresses cell growth and induces apoptosis in HepG2 cells. J Hepatol. 2003;39:580–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Tan B, Tan J, Du H, et al. HepaCAM inhibits clear cell renal carcinoma 786–0 cell proliferation via blocking PKCepsilon translocation from cytoplasm to plasma membrane. Mol Cell Biochem. 2014;391:95–102.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee LH, Moh MC, Zhang T, Shen S. The immunoglobulin-like cell adhesion molecule hepaCAM induces differentiation of human glioblastoma U373-MG cells. J Cell Biochem. 2009;107:1129–38.CrossRefPubMedGoogle Scholar
  13. 13.
    Yang S, Wu X, Luo C, Pan C, Pu J. Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma. World J Urol. 2010;28:473–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Moh MC, Shen S. The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adhes Migr. 2009;3:334–6.CrossRefGoogle Scholar
  15. 15.
    Zhang T, Moh MC, Lee LH, Shen S. The immunoglobulin-like cell adhesion molecule hepaCAM is cleaved in the human breast carcinoma MCF7 cells. Int J Oncol. 2010;37:155–65.CrossRefPubMedGoogle Scholar
  16. 16.
    Chung Moh M, Hoon Lee L, Shen S. Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. J Hepatol. 2005;42:833–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Song X, Wang Y, Du H, et al. Overexpression of hepacam inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer. Prostate. 2014;74:1023–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Togashi Y, Hayashi H, Terashima M, et al. Inhibition of beta-catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. J Thorac Oncol. 2015;10:93–101.CrossRefPubMedGoogle Scholar
  19. 19.
    Fan C, Jiang G, Zhang X, et al. Zbed3 contributes to malignant phenotype of lung cancer via regulating beta-catenin and P120-catenin 1. Mol Carcinog. 2015;54 Suppl 1:E138–47.CrossRefPubMedGoogle Scholar
  20. 20.
    Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–205.CrossRefPubMedGoogle Scholar
  21. 21.
    Yan HB, Wang XF, Zhang Q, et al. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis. 2014;35:867–76.CrossRefPubMedGoogle Scholar
  22. 22.
    Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004;64:1987–96.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Huanzhang Shao
    • 1
  • Yinjie Gu
    • 2
  • Junli Ding
    • 3
  • Peihua Lu
    • 3
  • Tingyan Ruan
    • 3
  • Wenbin Lu
    • 4
  1. 1.Department of Critical Care Medicine, Henan Provincial People’s HospitalAffiliated of Zhengzhou UniversityZhengzhouChina
  2. 2.Department of Critical Care Medicine, Affiliated Yixing People’s HospitalJiangsu UniversityYixingChina
  3. 3.Department of Medical OncologyWuxi People’s Hospital Affiliated to Nanjing Medical UniversityWuxiChina
  4. 4.Department of Medical OncologyWujin People’s Hospital Affiliated to Jiangsu UniversityChangzhouChina

Personalised recommendations